Treatment satisfaction higher in patients switching to Orladeyo
Preventive treatment with Orladeyo (berotralstat) was associated with improved treatment satisfaction among hereditary angioedema (HAE) patients who had switched from injectable therapies, according to a recent clinical trial analysis. BioCryst Pharmaceutical’s oral treatment also was well tolerated and associated with low HAE attack rates, as has been…